The United Kingdom’s Veterinary Medicines Directorate (VMD) and Swissmedic, Switzerland’s regulatory authority for therapeutic products, have signed a Memorandum of Understanding (MoU) to collaborate in the area of veterinary medicinal products. The MoU aims to promote a better understanding of regulatory frameworks and enhance the sharing of information.
Deputy CEO Gavin Hall of the VMD and Executive Director Raimund Bruhin of Swissmedic signed the MoU, which focuses on increased collaboration in the review of authorization applications for veterinary medicinal products. The joint review process is aimed at ensuring safe, high-quality, and effective medicines reach the respective markets.
Gavin Hall said that this is an exciting and important step in the development of valued relationships between the VMD and global regulatory bodies. With the increasing globalization of the veterinary medicines market, cooperation between regulators is crucial to ensure a harmonized approach to product authorization.
Gavin Hall stated that global solutions and harmonization are necessary for the present global environment. The industry as a whole, as well as both of our organizations, benefit from our collaboration with Swissmedic. We are providing greater opportunities to bring safe, high-quality, and effective medicines to our respective markets.”
The VMD and Swissmedic are currently refining the joint review process and plan to publish the details in the coming weeks. Companies with projects that would benefit from this collaboration are encouraged to contact the VMD’s Renee Sheehan at r.sheehan@vmd.gov.uk.
The MoU between the UK’s VMD and Swissmedic demonstrates the growing recognition of the importance of international cooperation in the regulation of veterinary medicinal products. The collaboration is expected to bring significant benefits to both organizations and to the industry, ultimately ensuring the availability of safe, effective, and high-quality veterinary medicines for animal health.
Source: Gov[Dot]UK
